




The relative strengths and weaknesses of Seelos Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seelos Therapeutics INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 5.4% points. The greatest weakness of Seelos Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 87% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	20,895
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,766
Liabilities, Non-Current	196
Other Assets	2,383
Other Compr. Net Income	641
Other Expenses	13,074
Other Liabilities	6,296
Other Net Income	-6,361
Other Revenues	8,416
Property and Equipment	601
Research and Development	5,375
Selling, General and Administrative Expense	15,377

Output Variable	Value in 1000 USD
Assets	23,879
Liabilities	17,258
Expenses	33,826
Revenues	8,416
Stockholders Equity	6,621
Net Income	-31,771
Comprehensive Net Income	-31,450
BaseVar	45,190
ECR before LimitedLiability	-83%
Economic Capital Ratio	134%